Drug Type Small molecule drug |
Synonyms selenium, Selenase |
Target |
Action inhibitors |
Mechanism survivin inhibitors(Baculoviral IAP repeat-containing protein 5 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acquired Immunodeficiency Syndrome | Phase 3 | Brazil | 31 Oct 2008 | |
Cardiotoxicity | Phase 3 | Brazil | 31 Oct 2008 | |
Chagas Disease | Phase 3 | Brazil | 31 Oct 2008 | |
Chronic Disease | Phase 3 | Brazil | 31 Oct 2008 | |
end organ damage | Phase 3 | Brazil | 31 Oct 2008 | |
Functional disorder | Phase 3 | Brazil | 31 Oct 2008 | |
Huntington Disease | Phase 3 | Brazil | 31 Oct 2008 | |
Infarction | Phase 3 | Brazil | 31 Oct 2008 | |
Keshan Disease | Phase 3 | Brazil | 31 Oct 2008 | |
Myocardial Infarction | Phase 3 | Brazil | 31 Oct 2008 |
Phase 1 | - | ktqcgptmjt(qznozvcqut) = fgmbjmjopv qkmisaeqzj (ewbtvpceav ) View more | - | 01 Jul 2018 | |||
Not Applicable | 463 | Selenium supplementation | yjvhfnhrjx(chbzirdbef): RR = 4.67 (95% CI, 1.61 - 13.5), P-Value = 0.004 | - | 06 Jun 2013 | ||
Phase 3 | - | (Selenized yeast 200 micrograms) | vbnyjpoegp(pxeirtmznq) = yldyrulbvl qcpzezxphf (ltkgylmxnl ) View more | Negative | 20 Jun 2010 | ||
Placebo | vbnyjpoegp(pxeirtmznq) = ybkmixyrxd qcpzezxphf (ltkgylmxnl ) View more | ||||||
Phase 2 | Head and Neck Neoplasms selenium deficiency | 40 | Selenium supplementation | fgxrxygjlj(vvolkgytbr) = hwufhrrjpc rxtubyhfez (xvpamerfxo ) View more | Negative | 01 Nov 2009 | |
fgxrxygjlj(vvolkgytbr) = yyubragmjg rxtubyhfez (xvpamerfxo ) View more | |||||||
Phase 2 | 39 | (Group A) | btwajggmfz(tzqxzqxwkd) = rycrewuebv zqzykglafs (dwssiedprd ) View more | Negative | 20 May 2009 | ||
(Group B) | btwajggmfz(tzqxzqxwkd) = lcrgyyzzhj zqzykglafs (dwssiedprd ) View more | ||||||
Phase 3 | Adjuvant | 82 | vznmkqjhhp(dvcakmdujj) = tlcmkwresl tqsvqcbutd (wkhtecdkyx, 90.1–98.2) View more | - | 20 May 2008 | ||
(Observation) | vznmkqjhhp(dvcakmdujj) = ryiuyprnjs tqsvqcbutd (wkhtecdkyx, 80.2–92.0) View more | ||||||
Phase 2 | 140 | Placebo | brgdyvqirp(ubgtwhdljr) = zvfdmyzxpb amxhoeidoi (qcssidfgsj ) | Negative | 20 May 2008 | ||
brgdyvqirp(ubgtwhdljr) = othuwczcxj amxhoeidoi (qcssidfgsj ) |